UCB SA (OTCMKTS:UCBJY) Sees Significant Growth in Short Interest

UCB SA (OTCMKTS:UCBJY) saw a significant increase in short interest during the month of October. As of October 15th, there was short interest totaling 21,017 shares, an increase of 88.6% from the September 30th total of 11,143 shares. Based on an average daily trading volume, of 108,523 shares, the days-to-cover ratio is presently 0.2 days. Approximately 0.0% of the company’s stock are short sold.

UCB Stock Down 0.5%

OTCMKTS UCBJY opened at $155.99 on Tuesday. UCB has a 12-month low of $110.55 and a 12-month high of $168.76. The company has a fifty day simple moving average of $124.91 and a two-hundred day simple moving average of $140.21.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on UCBJY. Jefferies Financial Group upgraded UCB from a “moderate sell” rating to a “hold” rating in a research note on Monday, August 3rd. Zacks Research upgraded shares of UCB from a “hold” rating to a “strong-buy” rating in a report on Tuesday, October 27th. Two research analysts have rated the stock with a Strong Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Buy”.

UCB Company Profile

UCB SA is a Belgium-based biopharmaceutical company focused on developing and commercializing medicines for severe diseases in neurology and immunology. The company serves patients and healthcare professionals internationally, with operations and commercial activities spanning Europe, North America and other global markets.

UCB’s neurology portfolio includes medicines such as Vimpat (lacosamide) and Briviact (brivaracetam) for epilepsy, as well as Fintepla (fenfluramine) for certain seizure disorders.